Investors in Synthetic Biology

Deep Ocean Capital (DOC) is an indipendent management company hosting Deep Blue Ventures, a Venture Capital fund investing in Deep Technologies. DOC was born in Rome with international/global ambitions, and is focused on AI for Aerospace and Health sectors. We are early stage venture capital investors. We love technology as a means to transform our planet for the better. We believe in co-creating economic value together with the ecosystem we are part of. Deep Blue Ventures is the first VC fund of DOC, it is an early stage deep tech fund, investing in outstanding deep technologies, and people able to harnessing them to great global success. Deep Blue Ventures investments are focused in that stage where companies find product- market fit to the point where they start to scale, across multiple industry sectors where market opportunities are clearly at international scale.

BlueYard backs founders at the earliest stages building the interconnected elements that can become the fabric of our future. A future where markets are open and decentralized, where we have solved our largest planetary challenges, where knowledge and data is liberated and humanity can live long and prosper.

Investment company founded by Hermann Hauser in Central Europe and invests primarily in early-stage (seed, Series A) start-ups from the DACH region. The focus is on scalable technologies with high innovation potential from the fields of AI, Digital Health, Synthetic Biology, Operating Systems, Electronics, and Quantum Computing, among others.

Navigare Ventures is an early-stage investor specializing in science-driven companies, focusing on deep tech sectors such as advanced computing, quantum technologies, synthetic biology, advanced materials, and data-driven life sciences. They are committed long-term investors, supporting companies from Seed to Series A and beyond, and emphasize forming enduring partnerships with founders. Navigare Ventures leverages their extensive industrial and scientific networks to provide capital, networks, and expertise to facilitate the transformation of science startups into successful enterprises.

Invivo Partners is a venture capital firm specializing in early-stage healthcare companies, led by Luis Pareras, Albert Ferrer, and Laura Rodríguez. With investments in 15 portfolio companies and 3 successful exits, their portfolio companies have collectively raised over 350M€ from global VCs. The team at Invivo Partners combines scientific, technical, and financial expertise to make impactful investments and drive growth in the health sector. With a strong focus on Technology Transfer and market trends, the firm aims to establish itself as a key player in Europe's biotech industry. Invivo Partners' investor base includes major institutional investors such as the European Investment Fund, Instituto de Crédito Oficial (ICO), Institut Català de Finances (ICF), Institut Valencià de Finances (IVF), Barcelona City Council, alongside a majority of private investors. Initial investments typically range from 2-4M€, with follow-on investments up to 10M€ per company after achieving specified milestones. The firm specializes in pre-seed and seed investments, particularly in companies at the preclinical stage, and also participates in Series A investments for companies approximately 1-2 years away from First-in-Human trials. Invivo Partners focuses primarily on European-based opportunities, with a special emphasis on Spanish biotechnology companies developing innovative drugs, particularly in Advanced Therapies and Synthetic Biology.